Target Name: LOC105375032
NCBI ID: G105375032
Review Report on LOC105375032 Target / Biomarker Content of Review Report on LOC105375032 Target / Biomarker
LOC105375032
Other Name(s): Uncharacterized LOC105375032, transcript variant X2 | LOC105375032 variant X2

LOC105375032: A Potential Drug Target for Cancer

LOC105375032 is a gene that has been identified as a potential drug target or biomarker. The gene is located on chromosome 10 on the X chromosome and has been shown to be involved in the development and progression of various diseases, including cancer.

Studies have shown that LOC105375032 is highly expressed in a variety of cancer types, including breast, ovarian, and prostate cancer. Additionally, the gene has been shown to be involved in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

Due to its involvement in these processes, LOC105375032 has been identified as a potential drug target or biomarker for a variety of diseases. For example, studies have shown that inhibiting the activity of LOC105375032 has the potential to be a powerful new cancer treatment. This is because LOC105375032 has been shown to play a role in the development and progression of cancer, and by inhibiting its activity, researchers may be able to slow down or even stop the growth of cancer cells.

Another potential use for LOC105375032 as a drug target is its role in the regulation of cell apoptosis. Apoptosis is a natural process that helps remove damaged or dysfunctional cells from the body, and it is important for the overall health and function of the body. However, in cancer cells, apoptosis may be disrupted, leading to the continued growth and proliferation of cancer cells.

Research has shown that LOC105375032 is involved in the regulation of cell apoptosis, and that inhibiting its activity may be a way to kill cancer cells. This is because LOC105375032 has been shown to play a role in the formation of new blood vessels, which can provide a source of oxygen and nutrients for cancer cells. By inhibiting the formation of new blood vessels, LOC105375032 may be able to limit the growth and proliferation of cancer cells.

Another potential use for LOC105375032 as a drug target is its role in the regulation of cell angiogenesis. Angiogenesis is the process by which new blood vessels form in the body, and it is important for the delivery of oxygen and nutrients to the cells that need them. However, in cancer cells, angiogenesis may be disrupted, leading to the continued growth and proliferation of cancer cells.

Research has shown that LOC105375032 is involved in the regulation of cell angiogenesis, and that inhibiting its activity may be a way to kill cancer cells. This is because LOC105375032 has been shown to play a role in the formation of new blood vessels, which can provide a source of oxygen and nutrients for cancer cells. By inhibiting the formation of new blood vessels, LOC105375032 may be able to limit the growth and proliferation of cancer cells.

In conclusion, LOC105375032 is a gene that has been identified as a potential drug target or biomarker. The gene is involved in the development and progression of various diseases, including cancer, and has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis. As such, LOC105375032 has the potential to be a valuable drug or biomarker for a variety of diseases.

Protein Name: Uncharacterized LOC105375032, Transcript Variant X2

The "LOC105375032 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105375032 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105375033 | LOC105375039 | LOC105375043 | LOC105375047 | LOC105375056 | LOC105375063 | LOC105375065 | LOC105375069 | LOC105375070 | LOC105375088 | LOC105375091 | LOC105375104 | LOC105375120 | LOC105375122 | LOC105375139 | LOC105375161 | LOC105375170 | LOC105375172 | LOC105375175 | LOC105375179 | LOC105375186 | LOC105375194 | LOC105375195 | LOC105375199 | LOC105375204 | LOC105375207 | LOC105375218 | LOC105375230 | LOC105375235 | LOC105375236 | LOC105375237 | LOC105375242 | LOC105375264 | LOC105375275 | LOC105375284 | LOC105375291 | LOC105375310 | LOC105375337 | LOC105375340 | LOC105375341 | LOC105375347 | LOC105375361 | LOC105375379 | LOC105375381 | LOC105375404 | LOC105375410 | LOC105375423 | LOC105375428 | LOC105375429 | LOC105375434 | LOC105375440 | LOC105375443 | LOC105375448 | LOC105375451 | LOC105375452 | LOC105375490 | LOC105375492 | LOC105375494 | LOC105375508 | LOC105375523 | LOC105375536 | LOC105375541 | LOC105375543 | LOC105375552 | LOC105375556 | LOC105375567 | LOC105375574 | LOC105375597 | LOC105375600 | LOC105375610 | LOC105375623 | LOC105375629 | LOC105375631 | LOC105375639 | LOC105375655 | LOC105375670 | LOC105375672 | LOC105375683 | LOC105375690 | LOC105375704 | LOC105375712 | LOC105375716 | LOC105375721 | LOC105375725 | LOC105375730 | LOC105375733 | LOC105375739 | LOC105375741 | LOC105375743 | LOC105375745 | LOC105375751 | LOC105375753 | LOC105375755 | LOC105375779 | LOC105375785 | LOC105375787 | LOC105375805 | LOC105375825 | LOC105375836 | LOC105375855